{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:15:35Z","timestamp":1783656935129,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ahj.2015.05.011","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T20:54:19Z","timestamp":1432328059000},"page":"490-497.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Farcomeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bartimoccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nocella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasa","family":"Vicario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-7068","authenticated-orcid":false,"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ahj.2015.05.011_bb0005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ahj.2015.05.011_bb0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.ahj.2015.05.011_bb0015","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ahj.2015.05.011_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","article-title":"Atrial fibrillation and the risk of myocardial infarction","volume":"174","author":"Soliman","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.ahj.2015.05.011_bb0025","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.14-2414","article-title":"Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors","volume":"147","author":"Pastori","year":"2015","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.ahj.2015.05.011_bb0030","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"issue":"30","key":"10.1016\/j.ahj.2015.05.011_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17300","article-title":"Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review","volume":"17","author":"Lane","year":"2013","journal-title":"Health Technol Assess"},{"issue":"16","key":"10.1016\/j.ahj.2015.05.011_bb0040","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.ahj.2015.05.011_bb0045","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ahj.2015.05.011_bb0050","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1073\/pnas.83.16.5861","article-title":"11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation","volume":"83","author":"Catella","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ahj.2015.05.011_bb0055","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.STR.23.10.1400","article-title":"Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin","volume":"23","author":"Tohgi","year":"1992","journal-title":"Stroke"},{"issue":"14","key":"10.1016\/j.ahj.2015.05.011_bb0060","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ahj.2015.05.011_bb0065","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ahj.2015.05.011_bb0070","first-page":"1462","article-title":"2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ahj.2015.05.011_bb0075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"issue":"19","key":"10.1016\/j.ahj.2015.05.011_bb0080","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ahj.2015.05.011_bb0085","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2015.05.011_bb0090","first-page":"637","article-title":"Classification of cerebrovascular diseases III","volume":"21","author":"Special report from the National Institute of Neurological Disorders and Stroke","year":"1990","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ahj.2015.05.011_bb0095","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ahj.2015.05.011_bb0100","first-page":"373","article-title":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects","volume":"79","author":"World Medical A","year":"2001","journal-title":"Bull World Health Organ"},{"issue":"17","key":"10.1016\/j.ahj.2015.05.011_bb0105","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ahj.2015.05.011_bb0110","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/sim.5647","article-title":"A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data","volume":"32","author":"Uno","year":"2013","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ahj.2015.05.011_bb0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1097-0258(20010130)20:2<237::AID-SIM654>3.0.CO;2-I","article-title":"Regression splines for threshold selection in survival data analysis","volume":"20","author":"Molinari","year":"2001","journal-title":"Stat Med"},{"issue":"17","key":"10.1016\/j.ahj.2015.05.011_bb0120","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":"Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2015.05.011_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"10.1016\/j.ahj.2015.05.011_bb0130","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2015.05.011_bb0135","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1160\/TH13-01-0054","article-title":"Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?","volume":"109","author":"Roldan","year":"2013","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ahj.2015.05.011_bb0140","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2015.05.011_bb0145","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2015.05.011_bb0150","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2015.05.011_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","article-title":"Atrial fibrillation and the risk of myocardial infarction","volume":"174","author":"Soliman","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"12 Suppl.","key":"10.1016\/j.ahj.2015.05.011_bb0160","first-page":"IV130","article-title":"Thromboxane biosynthesis in cardiovascular diseases","volume":"21","author":"Patrono","year":"1990","journal-title":"Stroke"},{"issue":"15","key":"10.1016\/j.ahj.2015.05.011_bb0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2015.05.011_bb0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2015.05.011_bb0175","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.112.145334","article-title":"Statins as antithrombotic drugs","volume":"127","author":"Violi","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2015.05.011_bb0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FJC.0000000000000102","article-title":"The use of statins to prevent postoperative atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 12 studies","volume":"64","author":"Zheng","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2015.05.011_bb0185","article-title":"Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion","author":"Cho","year":"2014","journal-title":"Heart Vessel"},{"issue":"3","key":"10.1016\/j.ahj.2015.05.011_bb0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11739-010-0440-3","article-title":"TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus","volume":"6","author":"Santilli","year":"2011","journal-title":"Intern Emerg Med"},{"issue":"1 Suppl.","key":"10.1016\/j.ahj.2015.05.011_bb0195","first-page":"I12","article-title":"Biosynthesis and pharmacological modulation of thromboxane in humans","volume":"81","author":"Patrono","year":"1990","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahj.2015.05.011_bb0200","first-page":"1012","article-title":"Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET\/EHRA consensus conference","volume":"106","author":"Kirchhof","year":"2011","journal-title":"Thromb Haemost"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315003622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315003622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:55:33Z","timestamp":1757570133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315003622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0002870315003622"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2015.05.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2015.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}